Loading...
Idorsia Ltd
IDRSF•PNK
Healthcare
Biotechnology
$2.25
$0.00(0.00%)
Idorsia Ltd (IDRSF) Financial Performance & Statements
Review Idorsia Ltd’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-26.17%
↓ 26.17%
Operating Income Growth
9.07%
↑ 9.07%
Net Income Growth
11.47%
↑ 11.47%
Operating Cash Flow Growth
41.17%
↑ 41.17%
Operating Margin
-317.82%
↓ 317.82%
Gross Margin
64.65%
↑ 64.65%
Net Profit Margin
-234.44%
↓ 234.44%
ROE
24.44%
↑ 24.44%
ROIC
-570.31%
↓ 570.31%
Idorsia Ltd (IDRSF) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Idorsia Ltd stock.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | $112.51M | $152.39M | $97.10M | $35.35M |
| Cost of Revenue | $179.59M | $7.15M | $6.27M | $18.03M |
| Gross Profit | -$67.08M | $145.24M | $90.84M | $17.32M |
| Gross Profit Ratio | -$0.60 | $0.95 | $0.94 | $0.49 |
| R&D Expenses | $143.67M | $293.56M | $383.33M | $414.21M |
| SG&A Expenses | $273.12M | $380.01M | $509.03M | $233.67M |
| Operating Expenses | $164.93M | $400.38M | $893.80M | $648.35M |
| Total Costs & Expenses | $344.52M | $407.53M | $900.07M | $648.35M |
| Interest Income | $0.00 | $16.11M | $48000.00 | $6.13M |
| Interest Expense | $0.00 | $20.67M | $17.17M | $27.94M |
| Depreciation & Amortization | $17.87M | $19.03M | $19.83M | $18.03M |
| EBITDA | -$319.49M | -$254.55M | -$783.09M | -$588.84M |
| EBITDA Ratio | -$2.84 | -$1.67 | -$8.06 | -$16.66 |
| Operating Income | -$232.01M | -$255.15M | -$802.97M | -$613.004M |
| Operating Income Ratio | -$2.06 | -$1.67 | -$8.27 | -$17.34 |
| Other Income/Expenses (Net) | -$31.31M | -$39.11M | -$17.12M | -$21.80M |
| Income Before Tax | -$263.32M | -$294.25M | -$820.09M | -$634.80M |
| Income Before Tax Ratio | -$2.34 | -$1.93 | -$8.45 | -$17.96 |
| Income Tax Expense | $434000.00 | $3.67M | $7.81M | -$210000.00 |
| Net Income | -$263.76M | -$297.92M | -$827.90M | -$634.60M |
| Net Income Ratio | -$2.34 | -$1.96 | -$8.53 | -$17.95 |
| EPS | -$1.45 | -$1.67 | -$4.67 | -$3.77 |
| Diluted EPS | -$1.45 | -$1.67 | -$4.67 | -$3.77 |
| Weighted Avg Shares Outstanding | $181.90M | $178.25M | $177.43M | $168.50M |
| Weighted Avg Shares Outstanding (Diluted) | $182.45M | $178.25M | $177.43M | $168.50M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan